The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Adicet Bio, Inc. Common Stock 007002108   784,422 968,183 SH   SOLE   968,183 0 0
Adverum Biotechnologies, Inc. Common Stock 00773U207   819,518 180,909 SH   SOLE   180,909 0 0
Alnylam Pharmaceuticals, Inc. Common Stock 02043Q107   634,890,168 1,392,303 SH   SOLE   1,392,303 0 0
Intellia Therapeutics, Inc. Common Stock 45826J105   63,950,724 3,702,995 SH   SOLE   3,702,995 0 0